# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $22 price target.
Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target f...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $16 p...
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of...
TD Cowen analyst Stacy Ku initiates coverage on Astria Therapeutics (NASDAQ:ATXS) with a Buy rating and announces Price Targ...
Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and lowers the price target f...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $16 p...
Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $22 price target.
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate.